MedPath

Dronabinol

Generic Name
Dronabinol
Brand Names
Marinol, Sativex, Syndros
Drug Type
Small Molecule
Chemical Formula
C21H30O2
CAS Number
1972-08-3
Unique Ingredient Identifier
7J8897W37S
Background

Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments .

Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are found throughout the body . While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms like Dronabinol or Nabilone), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers.

From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . The endocannabinoid system is widely distributed throughout the central and peripheral nervous system (via the Cannabinoid Receptors CB1 and CB2) and plays a role in many physiological processes such as inflammation, cardiovascular function, learning, pain, memory, stress and emotional regulation, and the sleep/wake cycle among many others . CB1 receptors are found in both the central and peripheral nervous system, and are most abundant in the hippocampus and amygdala, which are the areas of the brain responsible for short-term memory storage and emotional regulation. CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function .

Indication

Dronabinol is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Associated Conditions
Anorexia, Chemotherapy-Induced Nausea and Vomiting

Efficacy of Inhaled Cannabis for Acute Migraine Treatment

Phase 2
Completed
Conditions
Migraine
Cannabis
THC
CBD
Interventions
First Posted Date
2020-04-24
Last Posted Date
2023-02-28
Lead Sponsor
University of California, San Diego
Target Recruit Count
92
Registration Number
NCT04360044
Locations
🇺🇸

Center for Pain Medicine, UC San Diego, La Jolla, California, United States

Dronabinol for Post-operative Pain After Lumbar Fusion

Phase 4
Conditions
Post-operative Pain
Interventions
First Posted Date
2020-04-15
Last Posted Date
2021-02-12
Lead Sponsor
Jeffrey L Gum MD
Target Recruit Count
90
Registration Number
NCT04346407
Locations
🇺🇸

Norton Healthcare, Louisville, Kentucky, United States

Characterization of the Pharmacodynamic Response to Vaped THC

Phase 3
Withdrawn
Conditions
Vaping
THC
Interventions
First Posted Date
2020-04-09
Last Posted Date
2022-02-11
Lead Sponsor
Massachusetts General Hospital
Registration Number
NCT04340700

A RCT Comparing Dronabinol to a Placebo for Post-operative Pain in Total Joint Arthroplasty

Phase 3
Recruiting
Conditions
Osteoarthritis, Knee
Interventions
Other: Placebo
First Posted Date
2020-03-06
Last Posted Date
2023-01-10
Lead Sponsor
Colorado Joint Replacement
Target Recruit Count
460
Registration Number
NCT04298528
Locations
🇺🇸

Colorado Joint Replacement, Denver, Colorado, United States

Age-Related Effects of THC

Early Phase 1
Completed
Conditions
Tolerance
Adolescent Behavior
THC
Interventions
First Posted Date
2020-03-04
Last Posted Date
2023-11-09
Lead Sponsor
University of Chicago
Target Recruit Count
24
Registration Number
NCT04294966
Locations
🇺🇸

University of Chicago Hospital, Chicago, Illinois, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

The Pharmacokinetic and Pharmacodynamic Effects of Oral Cannabidiol (CBD) Under Acute and Chronic Exposure Conditions

Phase 1
Completed
Conditions
Cannabis, Drug Effects
Interventions
First Posted Date
2020-02-25
Last Posted Date
2024-08-07
Lead Sponsor
Johns Hopkins University
Target Recruit Count
75
Registration Number
NCT04283019
Locations
🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

Effects of Cannabis on Cognition and Endocannabinoid Levels in Bipolar Disorder Patients and Healthy Volunteers

Early Phase 1
Terminated
Conditions
Bipolar Disorder
Interventions
First Posted Date
2020-01-18
Last Posted Date
2024-05-10
Lead Sponsor
University of California, San Diego
Target Recruit Count
19
Registration Number
NCT04231643
Locations
🇺🇸

UC San Diego Medical Center, San Diego, California, United States

Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs

Phase 1
Completed
Conditions
Drug-Interactions
Interventions
First Posted Date
2019-12-17
Last Posted Date
2023-07-24
Lead Sponsor
Johns Hopkins University
Target Recruit Count
22
Registration Number
NCT04201197
Locations
🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis

Phase 1
Completed
Conditions
Cannabis
Ketamine
Interventions
Drug: Active Ketamine
Drug: Placebo Ketamine
First Posted Date
2019-12-16
Last Posted Date
2024-03-25
Lead Sponsor
Yale University
Target Recruit Count
22
Registration Number
NCT04199468
Locations
🇺🇸

VA Connecticut Healthcare System, West Haven, Connecticut, United States

Nutrition and Pharmacological Algorithm for Oncology Patients Study

Phase 4
Terminated
Conditions
Quality of Life
Pancreatic Cancer
Nutrition Poor
Head and Neck Cancer
Lung Cancer
Oncologic Complications
Interventions
First Posted Date
2019-11-07
Last Posted Date
2022-11-16
Lead Sponsor
Montefiore Medical Center
Target Recruit Count
1
Registration Number
NCT04155008
Locations
🇺🇸

Montefiore Hospital, Bronx, New York, United States

© Copyright 2025. All Rights Reserved by MedPath